Dermatologic and Aesthetic Implications of GLP‐1 Receptor Agonist‐Associated Weight Loss: Pathophysiology, Clinical Manifestations, and Management

Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have rapidly expanded in use for the management of type 2 diabetes and obesity, with growing adoption in cosmetically motivated populations. In parallel, clinicians are increasingly encountering patients with aesthetic concerns related to GLP‐1RA‐associated weight loss. Objective To review the aesthetic complications associated with GLP‐1RA therapy, examine underlying pathophysiologic mechanisms, and provide practical considerations for dermatologic and aesthetic management. Methods A narrative review of the literature was conducted, synthesizing clinical studies, body composition analyses, dermatologic reports, and aesthetic medicine literature addressing GLP‐1RA‐associated changes in facial volume, skin quality, and hair, as well as procedural considerations and management strategies. Findings GLP‐1RA‐associated weight loss is characterized by rapid adipose reduction, which may outpace dermal and connective tissue adaptation. This temporal mismatch contributes to facial volume loss, skin laxity, and changes in skin texture and hydration, often perceived as accelerated aging. Additional findings include hair shedding consistent with telogen effluvium and evolving body contour changes. These alterations occur within a dynamic soft‐tissue environment, complicating aesthetic intervention. Implications extend to neuromodulators, dermal fillers, energy‐based devices, and surgical planning, where treatment timing and modality selection are critical. Conclusion GLP‐1RA‐associated aesthetic changes represent a distinct and increasingly relevant clinical entity. Recognition of the underlying structural and physiologic mechanisms, combined with a staged and individualized approach to treatment, is essential to optimize outcomes and avoid overtreatment. Further prospective, GLP‐1RA‐specific research is needed to guide evidence‐based management in this evolving field.